Reporting from the 2021 Genitourinary Cancers Symposium, Karen Knudsen comments on results from CRPC studies looking at molecular determinants associated with long term response to apalutamide in the SPARTAN study, and the final results from the ACIS study testing the addition of apalutamide to abiraterone and prednisone in metastatic disease.
She also gives an overview of the final results from the TITAN study testing apalutamide in metastatic castration-sensitive setting receiving ADT.
- Abstract 8: Molecular determinants associated with long-term response to apalutamide in nonmetastatic castration-resistant prostate cancer, Felix Feng
- Abstract 9: Final results from ACIS, a randomized, placebo-controlled double-blind phase 3 study of apalutamide and abiraterone acetate plus prednisone versus AAP in patients with chemo-naive metastatic castration-resistant prostate cancer, Dana Rathkopf
- Abstract 11: Final analysis results from TITAN: A phase III study of apalutamide versus placebo in patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy, Kim Chi
This video was supported with an educational grant from Janssen Oncology